This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cancer Drug Stocks to Trade Ahead of ASCO

Stocks in this article: YMI EXEL DNDN MDVN BMY ARIA CELG

BOSTON ( TheStreet) --The American Society of Clinical Oncology (ASCO) annual meeting doesn't kick off for another two and half months, but it's not too early for investors and traders to start compiling a target list of cancer-focused drug stocks.

If it hasn't started already, the momentum in cancer drug stocks will emerge in the days and weeks leading up to May 18. That's the date this year when ASCO will post research abstracts to its annual meeting on the group's web site. The actual ASCO annual meeting doesn't begin until June 3, but if you're looking to trade cancer-focused drug stocks, waiting for June usually means being very late to the party.

For ASCO 2011 buzz, I'd look to prostate cancer stocks. Investors are kicking the tires on Medivation's (MDVN) MDV-3100, especially since the company is dropping strong hints about a phase III interim analysis towards the end of the year. Investors are also focused on Exelixis (EXEL) for cabozantinib both in prostate cancer and more immediately for upcoming results from a phase III study in medullary thyroid cancer.

This year's ASCO meeting will be the second go-around for Dendreon (DNDN) with an approved Provenge under its wing. With Provenge manufacturing capacity expanding, are oncologists, particularly those at academic medical centers, becoming more enthusiastic prescribers of Dendreon's groundbreaking cancer immunotherapy?

Skin cancer is likely to be a hot topic once again, led by Bristol-Myers Squibb's (BMY) Yervoy, which faces a key FDA approval decision at the end of the week. Bristol will use this year's ASCO meeting to both launch Yervoy but also to present new and commercially important data in front-line melanoma. Roche also figures to play heavily in the ASCO skin cancer discussion at with two drugs, PLX4032 and vismodegib (the latter partnered with Curis (CRIS).)

Sanofi-Aventis (SNY) will discuss negative results from a phase III study of iniparib in metastatic triple-negative breast cancer, looking for a silver lining in a disappointing clinical setback.

ASCO is a meeting in which drug research on solid tumors (breast, lung, colon, prostate) dominates, but blood-related cancer drugs also share the stage. The controversy over secondary malignancies tied (or not tied) to long-term use of Celgene's (CELG) multiple myeloma drug Revlimid is sure to be a story line at this year's meeting. Ariad Pharmaceuticals (ARIA) is likely to provide an update on a mid-stage study of ponatinib in chronic myeloid leukemia. Ariad and partner Merck (MRK) will also present detailed data from a positive phase III study of ridaforolimus in sarcoma.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs